MAP2K7 and melanoma: Anti-BRAF/MEK agents and immune checkpoint inhibitors (ICIs), which have proven their efficacy in metastatic melanoma patients, have been tested as an adjuvant therapy for resected stage III high-risk melanoma to reduce the risk of recurrence and improve distant metastases-free survival (DMFS) and overall survival (OS) [1,2,3,4,5,6].